Roivant Sciences Key Executives
This section highlights Roivant Sciences's key executives, including their titles and compensation details.
Find Contacts at Roivant Sciences
(Showing 0 of )
Roivant Sciences Earnings
This section highlights Roivant Sciences's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q3 | 2024 | 2025-02-10 | $-0.24 | $-0.13 |
| Read Transcript | Q2 | 2024 | 2024-11-12 | $-0.25 | $-0.29 |
| Read Transcript | Q1 | 2024 | 2024-08-09 | N/A | N/A |
| Read Transcript | Q4 | 2023 | 2024-05-30 | $-0.26 | $-0.23 |
| Read Transcript | Q3 | 2023 | 2024-02-13 | $-0.27 | $-0.21 |
| Read Transcript | Q2 | 2023 | 2023-11-13 | $-0.28 | $-0.26 |
| Read Transcript | Q1 | 2023 | 2023-08-14 | $-0.26 | $-0.38 |
Financial Statements
Access annual & quarterly financial statements for Roivant Sciences, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $124.80M | $61.28M | $55.29M | $23.80M | $67.69M |
| Cost of Revenue | $27.96M | $13.13M | $8.97M | $2.06M | $1.13M |
| Gross Profit | $96.83M | $48.15M | $46.32M | $21.74M | $66.56M |
| Gross Profit Ratio | 77.59% | 78.58% | 83.78% | 91.36% | 98.33% |
| Research and Development Expenses | $501.74M | $525.22M | $483.04M | $236.63M | $263.22M |
| General and Administrative Expenses | $- | $600.51M | $775.03M | $259.88M | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $675.04M | $600.51M | $775.03M | $259.88M | $335.77M |
| Other Expenses | $-5.32B | $97.75M | $139.89M | $596.13M | $- |
| Operating Expenses | $-4.13B | $1.22B | $1.40B | $1.09B | $598.98M |
| Cost and Expenses | $-4.12B | $1.24B | $1.41B | $1.09B | $600.11M |
| Interest Income | $146.43M | $32.18M | $369.00K | $1.42M | $17.99M |
| Interest Expense | $34.78M | $27.97M | $7.04M | $2.81M | $7.68M |
| Depreciation and Amortization | $22.04M | $18.86M | $5.93M | $175.16M | $-20.88M |
| EBITDA | $4.31B | $-1.18B | $-916.71M | $-895.74M | $-553.30M |
| EBITDA Ratio | 3453.86% | -1922.34% | -1658.12% | -3764.40% | -817.42% |
| Operating Income | $4.24B | $-1.18B | $-1.35B | $-1.07B | $-532.42M |
| Operating Income Ratio | 3399.19% | -1917.95% | -2444.82% | -4500.52% | -786.58% |
| Total Other Income Expenses Net | $11.41M | $-49.52M | $427.89M | $172.35M | $-28.56M |
| Income Before Tax | $4.25B | $-1.22B | $-923.75M | $-898.55M | $-560.99M |
| Income Before Tax Ratio | 3408.33% | -1998.75% | -1670.85% | -3776.20% | -828.77% |
| Income Tax Expense | $22.22M | $5.19M | $369.00K | $1.69M | $7.12M |
| Net Income | $4.35B | $-1.01B | $-845.26M | $-809.23M | $1.20B |
| Net Income Ratio | 3484.86% | -1646.59% | -1528.89% | -3400.86% | 1773.57% |
| EPS | $5.55 | $-1.42 | $-1.26 | $-1.18 | $5.21 |
| EPS Diluted | $5.23 | $-1.42 | $-1.26 | $-1.18 | $5.21 |
| Weighted Average Shares Outstanding | 783.25M | 712.79M | 669.75M | 684.79M | 215.35M |
| Weighted Average Shares Outstanding Diluted | 831.05M | 712.79M | 669.75M | 684.79M | 215.35M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.02M | $4.47M | $55.13M | $28.93M | $37.14M | $37.10M | $21.62M | $27.38M | $17.05M |
| Cost of Revenue | $259.00K | $2.05M | $3.98M | $4.41M | $3.67M | $3.27M | $4.21M | $9.39M | $8.32M |
| Gross Profit | $8.76M | $2.42M | $51.15M | $24.52M | $33.47M | $33.84M | $17.41M | $17.99M | $8.73M |
| Gross Profit Ratio | 97.13% | 54.15% | 92.78% | 84.75% | 90.12% | 91.20% | 80.51% | 65.71% | 51.18% |
| Research and Development Expenses | $141.59M | $142.35M | $133.21M | $120.90M | $123.72M | $131.98M | $125.13M | $131.86M | $125.53M |
| General and Administrative Expenses | $141.54M | $202.88M | $148.52M | $- | $197.28M | $- | $156.19M | $- | $- |
| Selling and Marketing Expenses | $- | $-1.09M | $- | $- | $- | $- | $156.19M | $- | $- |
| Selling General and Administrative Expenses | $141.54M | $201.79M | $148.52M | $169.62M | $197.28M | $164.35M | $156.19M | $120.30M | $163.52M |
| Other Expenses | $- | $- | $-110.39M | $- | $-5.35B | $-538.96M | $12.50M | $- | $- |
| Operating Expenses | $283.14M | $344.14M | $171.34M | $287.73M | $-5.03B | $-242.62M | $293.82M | $252.16M | $289.06M |
| Cost and Expenses | $283.40M | $346.19M | $175.32M | $294.93M | $-5.02B | $-239.35M | $298.04M | $261.54M | $297.38M |
| Interest Income | $61.85M | $69.77M | $72.13M | $83.46M | $31.95M | $14.30M | $16.71M | $14.28M | $10.25M |
| Interest Expense | $- | $- | $13.40M | $7.17M | $9.44M | $9.25M | $8.91M | $8.57M | $8.45M |
| Depreciation and Amortization | $- | $1.82M | $4.88M | $5.22M | $5.38M | $5.59M | $5.84M | $7.51M | $6.97M |
| EBITDA | $-274.38M | $-222.56M | $-179.07M | $5.11B | $-310.83M | $-311.34M | $-309.72M | $-163.13M | $-305.42M |
| EBITDA Ratio | -3042.59% | -4973.52% | -324.81% | 17674.27% | -836.92% | -839.17% | -1432.31% | -595.89% | -1791.12% |
| Operating Income | $-274.38M | $-341.71M | $-120.19M | $-266.00M | $5.06B | $276.45M | $-276.41M | $-234.17M | $-280.33M |
| Operating Income Ratio | -3042.59% | -7636.04% | -218.00% | -919.46% | 13626.50% | 745.14% | -1278.27% | -855.37% | -1643.96% |
| Total Other Income Expenses Net | $39.87M | $117.33M | $74.55M | $5.36B | $4.82B | $-50.95M | $-49.68M | $54.95M | $-101.75M |
| Income Before Tax | $-234.51M | $-224.38M | $70.14M | $-191.45M | $5.10B | $-327.36M | $-326.09M | $-179.22M | $-382.08M |
| Income Before Tax Ratio | -2600.50% | -5014.15% | 127.23% | -661.78% | 13727.35% | -882.35% | -1508.01% | -654.65% | -2240.66% |
| Income Tax Expense | $-25.57M | $12.46M | $12.65M | $-8.96M | $25.67M | $3.76M | $1.75M | $-3.79M | $2.82M |
| Net Income | $169.38M | $-230.18M | $95.30M | $-151.12M | $5.10B | $-304.33M | $-291.82M | $-33.62M | $-352.01M |
| Net Income Ratio | 1878.25% | -5143.78% | 172.85% | -522.35% | 13721.55% | -820.27% | -1349.50% | -122.80% | -2064.36% |
| EPS | $0.23 | $-0.31 | $0.13 | $-0.19 | $6.37 | $-0.40 | $-0.38 | $-0.05 | $-0.49 |
| EPS Diluted | $0.23 | $-0.31 | $0.12 | $-0.19 | $6.03 | $-0.40 | $-0.38 | $-0.05 | $-0.49 |
| Weighted Average Shares Outstanding | 722.72M | 735.47M | 735.82M | 802.86M | 800.59M | 770.23M | 759.27M | 742.54M | 713.32M |
| Weighted Average Shares Outstanding Diluted | 722.72M | 735.47M | 781.63M | 802.86M | 844.46M | 770.23M | 759.27M | 742.54M | 713.32M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $6.54B | $1.68B | $2.06B | $2.06B | $2.19B |
| Short Term Investments | $5.37M | $5.01M | $- | $77.70M | $- |
| Cash and Short Term Investments | $6.54B | $1.68B | $2.06B | $2.13B | $2.19B |
| Net Receivables | $82.81M | $37.64M | $6.73M | $13.83M | $15.28M |
| Inventory | $35.25M | $2.76M | $- | $- | $1 |
| Other Current Assets | $72.69M | $81.27M | $79.39M | $40.42M | $18.48M |
| Total Current Assets | $6.73B | $1.80B | $2.15B | $2.19B | $2.22B |
| Property Plant Equipment Net | $65.95M | $92.34M | $86.95M | $77.03M | $73.93M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $137.84M | $144.88M | $- | $- | $- |
| Goodwill and Intangible Assets | $137.84M | $144.88M | $- | $- | $- |
| Long Term Investments | $247.75M | $304.32M | $325.83M | $289.54M | $177.22M |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $39.11M | $49.48M | $25.82M | $36.13M | $6.66M |
| Total Non-Current Assets | $490.65M | $591.02M | $438.61M | $402.70M | $257.81M |
| Other Assets | $- | $- | $- | $100.00M | $- |
| Total Assets | $7.22B | $2.39B | $2.59B | $2.69B | $2.48B |
| Account Payables | $53.23M | $37.83M | $34.58M | $20.55M | $10.31M |
| Short Term Debt | $21.89M | $52.41M | $11.40M | $12.31M | $7.84M |
| Tax Payables | $10.47M | $542.00K | $708.00K | $- | $413.00K |
| Deferred Revenue | $4.17M | $12.44M | $10.15M | $5.92M | $3.62M |
| Other Current Liabilities | $177.00M | $169.22M | $127.53M | $180.18M | $69.94M |
| Total Current Liabilities | $266.76M | $272.45M | $184.37M | $218.96M | $92.12M |
| Long Term Debt | $477.86M | $428.99M | $272.49M | $232.66M | $173.04M |
| Deferred Revenue Non-Current | $- | $- | $13.74M | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $29.34M | $80.58M | $53.09M | $76.06M | $103.19M |
| Total Non-Current Liabilities | $507.19M | $509.57M | $339.33M | $308.73M | $276.24M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $773.95M | $782.02M | $523.70M | $527.69M | $368.36M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $- | $- | $- | $- | $- |
| Retained Earnings | $576.17M | $-3.77B | $-2.76B | $-1.92B | $-1.11B |
| Accumulated Other Comprehensive Income Loss | $-4.08M | $-2.62M | $-946.00K | $1.45M | $-2.35M |
| Other Total Stockholders Equity | $5.40B | $4.93B | $4.42B | $3.71B | $3.14B |
| Total Stockholders Equity | $5.97B | $1.16B | $1.66B | $1.80B | $2.03B |
| Total Equity | $6.45B | $1.61B | $2.06B | $2.06B | $2.11B |
| Total Liabilities and Stockholders Equity | $7.22B | $2.39B | $2.59B | $2.59B | $2.48B |
| Minority Interest | $479.95M | $449.82M | $404.49M | $264.22M | $76.53M |
| Total Liabilities and Total Equity | $7.22B | $2.39B | $2.59B | $2.59B | $2.48B |
| Total Investments | $247.75M | $304.32M | $325.83M | $289.54M | $177.22M |
| Total Debt | $499.75M | $481.40M | $283.89M | $244.98M | $180.88M |
| Net Debt | $-6.04B | $-1.20B | $-1.78B | $-1.81B | $-2.00B |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.99B | $1.97B | $5.68B | $6.54B | $6.67B | $1.41B | $1.43B | $1.68B | $1.53B |
| Short Term Investments | $3.16B | $3.43B | $-9.38M | $5.37M | $5.17M | $5.47M | $-10.29M | $- | $- |
| Cash and Short Term Investments | $5.15B | $5.40B | $5.68B | $6.54B | $6.68B | $1.41B | $1.44B | $1.68B | $1.53B |
| Net Receivables | $- | $22.68M | $82.81M | $63.19M | $54.62M | $39.91M | $39.91M | $37.64M | $29.45M |
| Inventory | $- | $- | $34.00M | $35.25M | $5.24M | $4.91M | $4.22M | $2.76M | $- |
| Other Current Assets | $16.02M | $380.50M | $72.69M | $81.23M | $70.32M | $73.72M | $77.66M | $81.37M | $85.37M |
| Total Current Assets | $5.36B | $5.80B | $6.00B | $6.73B | $6.81B | $1.55B | $1.56B | $1.80B | $1.65B |
| Property Plant Equipment Net | $104.46M | $56.65M | $63.15M | $65.95M | $68.75M | $73.11M | $87.90M | $92.34M | $91.93M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $136.01M | $137.84M | $150.41M | $140.62M | $145.04M | $- | $146.10M |
| Goodwill and Intangible Assets | $- | $- | $136.01M | $137.84M | $150.41M | $140.62M | $145.04M | $144.88M | $146.10M |
| Long Term Investments | $290.04M | $319.52M | $272.36M | $247.75M | $239.93M | $250.39M | $306.53M | $304.32M | $282.10M |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $33.88M | $28.73M | $23.43M | $39.11M | $46.85M | $49.80M | $36.02M | $49.48M | $36.59M |
| Total Non-Current Assets | $428.38M | $404.91M | $494.95M | $490.65M | $505.95M | $513.92M | $575.49M | $591.02M | $556.73M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $5.79B | $6.21B | $6.50B | $7.22B | $7.31B | $2.07B | $2.14B | $2.39B | $2.20B |
| Account Payables | $23.71M | $25.13M | $53.23M | $35.23M | $35.23M | $44.12M | $50.03M | $37.83M | $48.00M |
| Short Term Debt | $9.84M | $9.52M | $21.89M | $56.18M | $59.90M | $55.75M | $55.75M | $52.41M | $49.59M |
| Tax Payables | $576.00K | $1.36M | $23.44M | $10.47M | $25.22M | $1.36M | $1.24M | $542.00K | $813.00K |
| Deferred Revenue | $- | $3.41M | $2.66M | $4.17M | $4.70M | $5.80M | $10.57M | $12.44M | $7.80M |
| Other Current Liabilities | $107.36M | $516.83M | $164.03M | $138.33M | $119.85M | $158.51M | $127.40M | $169.22M | $138.06M |
| Total Current Liabilities | $141.48M | $556.25M | $215.04M | $266.76M | $244.90M | $265.55M | $245.00M | $272.45M | $244.25M |
| Long Term Debt | $- | $43.19M | $477.86M | $450.40M | $438.07M | $436.88M | $436.88M | $428.99M | $430.05M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $114.89M | $26.55M | $29.34M | $32.80M | $45.12M | $37.48M | $120.62M | $80.58M | $101.52M |
| Total Non-Current Liabilities | $114.89M | $69.74M | $386.12M | $507.19M | $483.20M | $474.36M | $557.50M | $509.57M | $531.57M |
| Other Liabilities | $- | $1 | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $256.38M | $625.99M | $601.16M | $773.95M | $728.10M | $739.91M | $802.51M | $782.02M | $775.82M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Retained Earnings | $460.40M | $395.58M | $671.47M | $576.17M | $727.29M | $-4.37B | $-4.06B | $-3.77B | $-3.74B |
| Accumulated Other Comprehensive Income Loss | $8.06M | $-18.04M | $-17.95M | $-4.08M | $-27.78M | $-3.07M | $-6.61M | $-2.62M | $-729.00K |
| Other Total Stockholders Equity | $4.72B | $5.20B | $5.40B | $5.39B | $249.03M | $5.28B | $4.98B | $4.93B | $4.70B |
| Total Stockholders Equity | $5.19B | $5.58B | $5.44B | $5.97B | $6.09B | $948.53M | $910.73M | $1.16B | $955.52M |
| Total Equity | $5.54B | $6.01B | $5.90B | $6.45B | $6.58B | $1.33B | $1.33B | $1.61B | $1.43B |
| Total Liabilities and Stockholders Equity | $5.79B | $6.21B | $6.50B | $7.22B | $7.31B | $2.07B | $2.14B | $2.39B | $2.20B |
| Minority Interest | $346.50M | $427.09M | $459.98M | $479.95M | $494.82M | $377.10M | $423.41M | $449.82M | $471.62M |
| Total Liabilities and Total Equity | $5.79B | $6.21B | $6.50B | $7.22B | $7.31B | $2.07B | $2.14B | $2.39B | $2.20B |
| Total Investments | $3.45B | $3.75B | $262.98M | $247.75M | $239.93M | $250.39M | $296.24M | $304.32M | $282.10M |
| Total Debt | $100.31M | $52.71M | $379.06M | $499.75M | $506.58M | $497.98M | $492.63M | $481.40M | $479.64M |
| Net Debt | $-1.89B | $-1.92B | $-5.30B | $-6.04B | $-6.16B | $-910.25M | $-941.46M | $-1.20B | $-1.05B |
Annual Cash Flow
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $4.23B | $-1.12B | $-924.12M | $-900.23M | $-519.39M |
| Depreciation and Amortization | $22.04M | $18.86M | $5.93M | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $- |
| Stock Based Compensation | $199.63M | $217.78M | $564.96M | $84.96M | $- |
| Change in Working Capital | $19.04M | $6.34M | $15.72M | $71.94M | $15.30M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $22.68M | $4.36M | $15.40M | $3.75M | $6.60M |
| Other Working Capital | $-3.65M | $1.99M | $316.00K | $68.19M | $8.70M |
| Other Non Cash Items | $-5.24B | $29.09M | $-340.22M | $191.20M | $-257.73M |
| Net Cash Provided by Operating Activities | $-765.27M | $-843.39M | $-677.73M | $-552.14M | $-761.83M |
| Investments in Property Plant and Equipment | $-1.38M | $-12.69M | $-17.44M | $-5.81M | $-4.92M |
| Acquisitions Net | $-36.98M | $107.86M | $-39.00K | $- | $1.77B |
| Purchases of Investments | $- | $- | $- | $- | $-68.38M |
| Sales Maturities of Investments | $- | $- | $320.17M | $- | $16.44M |
| Other Investing Activities | $5.24B | $-139.43M | $600.00K | $-25.90M | $-20.05M |
| Net Cash Used for Investing Activities | $5.20B | $-44.27M | $303.30M | $-31.70M | $1.69B |
| Debt Repayment | $-30.70M | $129.75M | $14.81M | $- | $-32.06M |
| Common Stock Issued | $438.56M | $379.71M | $- | $455.76M | $1.35B |
| Common Stock Repurchased | $- | $- | $- | $- | $-1.19B |
| Dividends Paid | $-6.00M | $- | $- | $- | $- |
| Other Financing Activities | $17.51M | $-10.00M | $291.98M | $508.00K | $83.48M |
| Net Cash Used Provided by Financing Activities | $419.36M | $499.46M | $306.79M | $456.26M | $217.16M |
| Effect of Forex Changes on Cash | $616.00K | $6.28M | $- | $- | $- |
| Net Change in Cash | $4.86B | $-381.92M | $-67.64M | $-127.58M | $- |
| Cash at End of Period | $6.55B | $1.69B | $2.07B | $2.14B | $2.19B |
| Cash at Beginning of Period | $1.69B | $2.07B | $2.14B | $2.27B | $849.55M |
| Operating Cash Flow | $-765.27M | $-843.39M | $-677.73M | $-552.14M | $-761.83M |
| Capital Expenditure | $-1.38M | $-12.69M | $-17.44M | $-5.81M | $-4.92M |
| Free Cash Flow | $-766.65M | $-856.08M | $-695.16M | $-557.94M | $-766.75M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | $25.25M | $-187.10M | $57.49M | $-182.50M | $5.07B | $-331.12M | $-327.85M | $-60.86M | $-352.01M |
| Depreciation and Amortization | $-48.36M | $1.82M | $4.88M | $5.22M | $5.38M | $5.59M | $5.84M | $5.95M | $6.97M |
| Deferred Income Tax | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $155.35M | $- | $50.19M | $46.72M | $54.33M | $49.32M | $49.26M | $25.28M | $- |
| Change in Working Capital | $58.42M | $10.31M | $-68.73M | $15.96M | $21.20M | $17.13M | $-35.24M | $21.18M | $2.74M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $54.00K | $7.21M | $-25.27M | $20.89M | $-8.35M | $-1.80M | $11.94M | $-9.61M | $7.20M |
| Other Working Capital | $58.37M | $3.10M | $-43.47M | $-4.93M | $29.54M | $18.93M | $-47.18M | $30.79M | $-4.46M |
| Other Non Cash Items | $-397.92M | $-91.83M | $-236.66M | $6.13M | $-5.36B | $62.66M | $58.06M | $-170.64M | $119.71M |
| Net Cash Provided by Operating Activities | $-207.25M | $-266.81M | $-192.83M | $-108.46M | $-210.45M | $-196.43M | $-249.93M | $-179.09M | $-222.59M |
| Investments in Property Plant and Equipment | $-1.83M | $-996.00K | $-965.00K | $-349.00K | $-355.00K | $-275.00K | $-403.00K | $-1.62M | $-508.00K |
| Acquisitions Net | $-110.39M | $110.39M | $- | $-804.00K | $- | $- | $- | $114.56M | $-3.09M |
| Purchases of Investments | $-658.54M | $-3.40B | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $960.00M | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $264.82M | $- | $- | $8.08M | $5.23B | $-36.18M | $508.00K | $614.00K | $88.00K |
| Net Cash Used for Investing Activities | $454.07M | $-3.29B | $-965.00K | $6.93M | $5.23B | $-36.45M | $105.00K | $113.55M | $-3.51M |
| Debt Repayment | $-49.09M | $-1.83M | $-7.67M | $-7.66M | $-7.57M | $-7.81M | $-7.81M | $-8.04M | $-7.42M |
| Common Stock Issued | $- | $7.27M | $- | $238.73M | $238.73M | $221.53M | $- | $217.25M | $163.03M |
| Common Stock Repurchased | $-243.35M | $-106.05M | $-648.38M | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $19.49M | $-6.18M | $-24.96M | $5.57M | $-23.29M | $15.86M | $15.29M | $1.12M | $-1.11M |
| Net Cash Used Provided by Financing Activities | $-272.95M | $-109.07M | $-660.62M | $-32.62M | $236.64M | $207.87M | $7.48M | $210.33M | $154.50M |
| Effect of Forex Changes on Cash | $-1.07M | $5.04M | $-2.74M | $-855.00K | $3.04M | $-1.45M | $-117.00K | $- | $- |
| Net Change in Cash | $31.76M | $-3.66B | $-857.15M | $-135.01M | $5.26B | $-26.46M | $-242.47M | $151.08M | $- |
| Cash at End of Period | $2.00B | $1.97B | $5.69B | $6.55B | $6.69B | $1.42B | $1.45B | $1.69B | $1.53B |
| Cash at Beginning of Period | $2.03B | $5.68B | $6.55B | $6.69B | $1.42B | $1.45B | $1.69B | $1.54B | $1.60B |
| Operating Cash Flow | $-207.25M | $-266.81M | $-192.83M | $-108.46M | $-210.45M | $-196.43M | $-249.93M | $-179.09M | $-222.59M |
| Capital Expenditure | $-1.83M | $-996.00K | $-965.00K | $-349.00K | $-355.00K | $-275.00K | $-403.00K | $-1.62M | $-508.00K |
| Free Cash Flow | $-209.08M | $-267.80M | $-193.79M | $-108.81M | $-210.81M | $-196.70M | $-250.34M | $-180.71M | $-223.10M |
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
$11.69
Stock Price
$8.34B
Market Cap
908
Employees
London, None
Location
Revenue (FY 2023)
$124.80M
103.6% YoY
Net Income (FY 2023)
$4.35B
531.0% YoY
EPS (FY 2023)
$5.23
468.3% YoY
Free Cash Flow (FY 2023)
$-766.65M
10.4% YoY
Profitability
Gross Margin
77.6%
Net Margin
3484.9%
ROE
72.9%
ROA
60.2%
Valuation
P/E Ratio
1.88
P/S Ratio
65.46
EV/EBITDA
0.49
Market Cap
$8.34B
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-765.27M
9.3% YoY
Free Cash Flow
$-766.65M
10.4% YoY
Balance Sheet Summary
Total Assets
$7.22B
202.2% YoY
Total Debt
$499.75M
3.8% YoY
Shareholder Equity
$5.97B
265.0% YoY
Dividend Overview
No Dividend Data
Roivant Sciences Ltd. doesn't currently pay dividends.
Roivant Sciences Dividends
Explore Roivant Sciences's dividend history, including dividend yield, payout ratio, and historical payments.
Roivant Sciences News
Read the latest news about Roivant Sciences, including recent articles, headlines, and updates.
Roivant Sciences: Primed For Growth With A De-Risked Pipeline
Roivant Sciences has strengthened its financial position through strategic divestitures, boasting $5.2 billion in cash and assets, enabling robust funding for its late-stage pipeline. The company's FcRn inhibitor platform, led by IMVT-1402, shows promise in autoimmune diseases, with positive clinical readouts validating its potential. Priovant's brepocitinib, targeting TYK2/JAK1 pathways, is advancing in Phase 3 trials for Dermatomyositis and Non-Infectious Uveitis, addressing significant unmet needs.
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced next phase of growth including changes to its leadership team and the expanded development of IMVT-1402 into two new indications, SjD and CLE.
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study in CIDP.
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP.
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences, Ltd. (Nasdaq: ROIV)), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology against Moderna, Inc. and certain affiliates. Together, the enforcement actions target alleged infringing activities in 30 countries.
Roivant Sciences Ltd. (ROIV) Q3 2024 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV ) Q3 2024 Earnings Conference Call February 10, 2025 8:00 AM ET Company Participants Stephanie Lee - IR Matt Gline - CEO Conference Call Participants David Risinger - Leerink Partners Dennis Ding - Jefferies Yaron Werber - TD Cowen Brian Cheng - JPMorgan Yatin Suneja - Guggenheim Securities Douglas Tsao - H.C.
Roivant Sciences Tops Q3 Expectations
Biopharmaceutical company Roivant Sciences (ROIV 0.18%) reported earnings for the third quarter of 2024 on Monday, Feb. 10, that topped analysts' consensus estimates. Q3 revenue of $9.02 million surpassed estimates of $5 million, reflecting the company's strategic momentum.
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2024, and provided a business update. Brepocitinib to be developed in third indication, cutaneous sarcoidosis (CS), an orphan indication with high unmet need; Phase 2 study initiation expected in second quarter of calendar year with topline data in second half of calendar year 2026 IMVT-1402 development is rapidly progressing with six Investigational New Drug (IND) applications cleared and pivotal studies in Graves' disease (GD) and difficult-to-treat rheumatoid arthritis (D2T RA) initiated Batoclimab topline results from pivotal trial in myasthenia gravis (MG) and initial results from period 1 of trial in chronic inflammatory demyelinating polyneuropathy (CIDP) expected by March 31, 2025 Progress in ongoing LNP litigation, with the summary judgment phase in the Moderna case taking place across the second and third quarters of calendar year 2025 and a jury trial scheduled for September 2025 Roivant reported consolidated cash, cash equivalents, restricted cash and marketable securities of approximately $5.2 billion at December 31, 2024, not including a one-time regulatory milestone of $75 million received in January for the approval of VTAMA in atopic dermatitis and $113 million of external capital raised in Immunovant's January private placement “Roivant has broadened our clinical pipeline with the newly announced trial of brepocitinib in cutaneous sarcoidosis.
Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)
Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed, trading flat while S&P 500 gained 19% since April. Brepocitinib shows promise for NIU treatment with Phase 2 success, but faces challenges including safety concerns and competition from Humira in the $1.5B market. Mosliciguat, targeting PH-ILD, could compete with Tyvaso ($433.8M in Q3 sales) through once-daily dosing and novel mechanism, pending Phase 2 results.
Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care
Zest is initially focused on treating the millions of Americans with inflammatory skin diseases who are currently overprescribed expensive biologics Zest is initially focused on treating the millions of Americans with inflammatory skin diseases who are currently overprescribed expensive biologics
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025
BASEL, Switzerland and LONDON and NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, February 10, 2025, to report its financial results for the third quarter ended December 31, 2024, and provide a business update.
Trump Index: 6 Companies Linked to Trump's Cabinet Worth Watching
President Donald Trump's cabinet is often referred to as "The Avengers," with each member being accomplished in their field of expertise. Trump's cabinet has an overwhelming number of successful businessmen and businesswomen who were leaders in the business world prior to entering the government.
Roivant Sciences: A Biotech Growth Play With Major Ambitions
Roivant Sciences leverages its "Vant" model to develop and monetize drug candidates through subsidiaries, ensuring rapid advancement in therapeutic pipelines. Late-stage assets like Brepocitinib, IMVT-1402, and Mosliciguat position Roivant for significant clinical and commercial milestones by 2025. Strategic divestitures, like Dermavant's sale to Organon for $1.2 billion, support shareholder value through share buybacks and bolster financial stability.
Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV ) Q2 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Ben Zimmer - Chief Executive Officer, Priovant Conference Call Participants Louise Chen - Cantor Brian Cheng - JPMorgan Joyce Zhou - TD Cowen Andy Chen - Wolfe Research Douglas Tsao - H.C.
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
BASEL, Switzerland and LONDON and NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 12, 2024, to report its financial results for the second quarter ended September 30, 2024, and provide a business update.
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
The acquisition expands Organon's dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S. The acquisition expands Organon's dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S.
Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility
Roivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and Dermavant have bolstered Roivant's cash reserves. Key potential catalysts include Immunovant's batoclimab in Phase 3 trials and namilumab in a Phase 2 trial, though drug candidate performance remains a critical risk factor.
Does Montes Archimedes Acquisition (ROIV) Have the Potential to Rally 35.12% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 35.1% in Montes Archimedes Acquisition (ROIV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
BASEL, Switzerland and LONDON and NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced its previously undisclosed pipeline program mosliciguat, a potential first-in-class, inhaled, once-daily sGC activator with targeted delivery to the lungs via dry powder inhaler, at Pulmovant. Pulmovant presented data from the proof-of-concept Phase 1b ATMOS study during the ERS Congress in Vienna, Austria.
Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress
WALTHAM, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Pulmovant, a Roivant (Nasdaq: ROIV) company, today announced the presentation of data from the proof-of-concept Phase 1b ATMOS1 study during the ERS Congress in Vienna, Austria. ATMOS (NCT03754660) evaluated mosliciguat, a potential first-in-class, inhaled sGC activator with targeted delivery to the lungs and once-daily administration, in PH patients.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ROIV.